NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis $1.64 -0.07 (-4.09%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About Compugen Stock (NASDAQ:CGEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Compugen alerts:Sign Up Key Stats Today's Range$1.63▼$1.6850-Day Range$1.60▼$2.1052-Week Range$0.53▼$3.03Volume153,045 shsAverage Volume176,741 shsMarket Capitalization$146.35 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingBuy Company OverviewCompugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More… 10 EV Stocks to Buy Right Now (Ad)EV stocks are red hot. We’ve found TEN that we think will produce big wins for early investors. There’s no charge to view this report, so I urge everyone to check out the 10 stocks we’ve found as soon as possible.Click here to view all 10 stocks right away. Compugen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks44th Percentile Overall ScoreCGEN MarketRank™: Compugen scored higher than 44% of companies evaluated by MarketBeat, and ranked 644th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.15 to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -16.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.74% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Compugen has recently decreased by 17.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.74% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Compugen has recently decreased by 17.11%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News SentimentN/A News SentimentCompugen has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Compugen this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Stock News HeadlinesCompugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024October 29, 2024 | prnewswire.comCompugen to Present New Clinical Data at SITC 2024October 7, 2024 | prnewswire.comUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!November 5, 2024 | Darwin (Ad)Biomerica (NASDAQ:BMRA) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comGSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trialSeptember 14, 2024 | msn.comCompugen to Present at Single Cell Genomics 2024 ConferenceSeptember 9, 2024 | prnewswire.comCompugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 29, 2024 | prnewswire.comCompugen LtdAugust 27, 2024 | money.usnews.comSee More Headlines CGEN Stock Analysis - Frequently Asked Questions How have CGEN shares performed this year? Compugen's stock was trading at $1.98 at the beginning of 2024. Since then, CGEN shares have decreased by 17.2% and is now trading at $1.64. View the best growth stocks for 2024 here. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) released its earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.06. The biotechnology company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $2.68 million. Who are Compugen's major shareholders? Compugen's top institutional investors include Taylor Frigon Capital Management LLC (1.35%) and Joel Isaacson & Co. LLC (0.06%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXDW), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL) and Block (SQ). Company Calendar Last Earnings8/06/2024Today11/05/2024Next Earnings (Confirmed)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees68Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+143.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio10.93 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-1.19% Return on Equity-16.10% Return on Assets-9.23% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.12 Sales & Book Value Annual Sales$33.46 million Price / Sales4.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book2.25Miscellaneous Outstanding Shares89,240,000Free Float80,759,000Market Cap$146.35 million OptionableOptionable Beta2.64 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:CGEN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.